

Amendments to the Specification

Please replace the paragraph on page 7, line 1, with the following amended paragraph:

In a preferred embodiment, the present invention provides a method of treating or preventing a T cell mediated inflammatory or autoimmune disease comprising administering a pharmaceutical composition which comprises a molecule comprising a V_H-CDR3 region and a V_L-CDR3 region set forth in SEQ ID NO:1 and SEQ ID NO:10, respectively, and a pharmaceutically acceptable carrier. In another preferred embodiment the pharmaceutical composition comprises a V_H domain and a V_L domain set forth in SEQ ID NO:19 and SEQ ID NO:2728, respectively, and a pharmaceutically acceptable carrier. In yet another preferred embodiment the pharmaceutical composition comprises a single chain Fv molecule (scFv) set forth in SEQ ID NO:37, having corresponding polynucleotide sequence SEQ ID NO:38, and a pharmaceutically acceptable carrier.

Please replace the paragraph on page 13, line 1, with the following amended paragraph:

V_H refers to the variable heavy chain, V_L refers to the variable light chain, CDR3 refers to complementarity determining region 3. In certain preferred embodiments the present invention provides a method of treating or preventing T cell mediated inflammatory or autoimmune disease comprising administering a ~~composition~~ a composition comprising a therapeutically effective molecule comprising a V_H-CDR3 region having a polypeptide sequence as set forth in any one of SEQ ID NOS: 1-9 and a corresponding V_L-CDR3 region having a polypeptide sequence as set forth in any one of SEQ ID NOS: 10-18, and a pharmaceutically

Appln. No. 10/561,396
Amd. dated January 22, 2009
Reply to Office Action of October 2, 2008

acceptable carrier. The corresponding polynucleotide sequences of the V_H-CDR3 and V_L-CDR3 regions as set forth in any one of SEQ ID NOS: 39-47 and SEQ ID NOS: 48-56, respectively. The polynucleotide sequences are presented in Table 3.